Adding pembrolizumab to carboplatin and etoposide improved response rates and OS vs chemotherapy alone in metastatic NEPC in ...
Posters presented at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid examined how genomic testing ...
ESMO Congress 2026 will feature updated findings on KRAS inhibitors, bispecific T-cell engagers, and other key modalities in ...
In October 2026, the Vatican announced that Pope Leo XIV had undergone a right lower lobectomy to remove a lung nodule that ...
Experts preview 6 breast cancer trials to watch at ESMO 2026, including KEYNOTE-B49, evERA, DESTINY-Breast11, SWITCH, ...
Adults in the US with previously treated locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations can ...
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease ...
Sofetabart mipitecan (Sofe-M), an investigational folate receptor α (FRα)–directed antibody-drug conjugate (ADC), yielded ...
Oana Danciu, MD, explained why phase 1 breast cancer trials are moving earlier in the treatment course and how disease stability guides patient selection. Matthew J. Frigault, MD, and Adam D. Cohen, ...
Yu, MD, discusses the background of REZILIENT3 and her key takeaways on zipalertinib in EGFR exon 20-mutated NSCLC. This study focused on EGFR exon 20-positive lung cancer, which is a small subset of ...
Intismeran autogene plus pembrolizumab cut the risk of recurrence or death by 42% vs pembrolizumab alone in resected stage IIB-IV melanoma.
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results